Jean-Claude Provost - Mar 1, 2024 Form 4 Insider Report for Lantheus Holdings, Inc. (LNTH)

Role
Chief Medical Officer
Signature
/s/ Eric Green, attorney-in-fact
Stock symbol
LNTH
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 08:20 PM
Previous filing
Mar 6, 2023
Next filing
Mar 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LNTH Common Stock Award $0 +18.6K +89.15% $0.00 39.4K Mar 1, 2024 By Theranostics Consulting SAS F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LNTH Stock Option (right to buy) Award $0 +11K $0.00 11K Mar 1, 2024 Common Stock 11K $64.64 By Theranostics Consulting SAS F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 6,188 restricted stock units that vest in equal installments over a three-year period and 12,376 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period.
F2 The option vests in three equal annual installments beginning on March 1, 2025.